Skip to content
Get the Balanced News app for a better experience!
The Balanced News Logo
Analytics
The Balanced News Logo

Stay Balanced, Stay Informed

Menu
  • Browse News
  • Underreported Stories
  • Curated Feeds
  • Insights
  • Analytics
  • Our Writers
  • About Us
  • Download App
Learn
  • How It Works
  • Bias Detection
  • Lens Score
  • Source Bias Checker
  • Accountability
  • Custom Feeds
Newsroom
  • Writers & Analysts
  • About TBN
  • Editorial Standards
  • Corrections Policy
  • Our Partners
  • Insights
Socials
  • Youtube
  • Instagram
  • X
  • Facebook
News Categories
  • Trending
  • Politics
  • Sports
  • Business
  • Tech
  • Entertainment
  • Health
  • Science
  • Crime
  • Lifestyle
  • National
  • International
  • Good News
  • Crypto

Get Our App

Available for iOS and Android


LensFeedsInsightsAnalyticsTrendingGood NewsSportsPoliticsBusinessCrimeTechEntertainmentHealthNationalInternational

© 2026 The Balanced News. All rights reserved.

About UsEditorial StandardsCorrectionsHelp & SupportPrivacy PolicyTerms & Conditions
India's Pharma Market Gains and CDMO Growth Amid Global Supply-Chain Shifts

Categories

Categories

Related Coverage

Select a news story to see related coverage from other media outlets.

Related Coverage

Select a news story to see related coverage from other media outlets.

  1. Home
  2. /
  3. Business

India's Pharma Market Gains and CDMO Growth Amid Global Supply-Chain Shifts

Analysed 25 Jun 2026·2 sources analysed·Chittorgarh, India·Business
India's Pharma Market Gains and CDMO Growth Amid Global Supply-Chain ShiftsPreviousNext

India's pharmaceutical sector is experiencing notable shifts as multinational companies regain market share and contract manufacturers expand amid global supply-chain realignments. Big Pharma has increased its share in the Indian drug market for the second consecutive year, driven by innovative specialty medicines and chronic care products. Concurrently, Indian contract development and manufacturing organisations (CDMOs) are capitalizing on global diversification away from China, with firms like Sai Life Sciences investing in capacity to meet rising demand, although regulatory processes may delay immediate benefits.

TBN's observations

First-hand measurement across 2 sources

We measured how 2 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is positive (72/100). Lens Score 36/100 — moderate-to-low public interest.

Outlets analysed (first-hand measurement by TBN's Bias Engine):

  • economictimes— balanced framing, positive sentiment
  • thefinancialexpress— balanced framing, positive sentiment
Political Bias
0%100%0%
Sentiment
72%
AI analysis of 2 sources · Published under editorial oversight by The Balanced News
Analysed 25 Jun 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 2 sources
● Left 0%● Center 100%● Right 0%

The articles present a largely economic and industry-focused perspective without explicit political framing. They highlight multinational pharmaceutical companies' market share gains and Indian CDMOs' growth opportunities due to global supply-chain diversification. The coverage includes corporate viewpoints and market data, reflecting business and regulatory considerations rather than political debates or partisan positions.

Sentiment — Positive (72/100)

The overall tone across the articles is cautiously optimistic, emphasizing growth and opportunity in India's pharmaceutical sector. While acknowledging challenges such as regulatory scrutiny and past market share declines, the coverage focuses on positive developments like increased investment, market share recovery, and strategic positioning in global supply chains.

How 2 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

Reviewed byMrunal Wange· Business & Economy Editor· Edited byOjas Kale
← Previous
Pavan Kaushik Advocates Recognizing Corporate Communication as 'The Fifth Estate' in New Book
Next →
First Norton Atlas Rolls Out at TVS Hosur Plant Ahead of Global Launch
SourceTheir headlineBiasSentiment
economictimesIndia's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesCenterPositive
thefinancialexpressBig Pharma extends India market gains for second straight yearCenterPositive

Coverage timeline

thefinancialexpress broke this story on 24 Jun, 02:34 pm. Other outlets followed.

  1. 1
    thefinancialexpress24 Jun, 02:34 pm
    Big Pharma extends India market gains for second straight year
  2. 2
    economictimes25 Jun, 08:42 am
    India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life Sciences

Lens Score breakdown

36/100
Public interest0/100
Coverage gap100%

Story is receiving appropriate media attention relative to public interest.

Who's involved

Institutions and figures named across source coverage.

Corporate
Dr. Reddy's LaboratoriesPfizerNovartis AGAstraZenecaSanofi IndiaUniversal NutriscienceJanssen Pharmaceutica NVEli LillySai Life Sciences

Story context

Category
Business
Location
Chittorgarh, India
Sources analysed
2
Last analysed
25 Jun 2026
Key entities
Pharmaceutical industryMultinational corporationIndiaCroreAnti-obesity medicationIQVIAMarket shareDiabetesSemaglutideMedicationGlucagon-like peptide-1Patent